Bring Your Boots: Wading Through GI PCR Panel Diagnos Saint Luke's Stewardship Applications HEALTH SYSTEM Nicholas Bennett, PharmD, BCIDP, Sarah Boyd, MD, Jeffrey Sattler, PharmD, DO, Ginny Boos, PhD, Cara Johnston, RN,

Background

- Infectious diarrhea is a common cause of emergency department (ED) visits and hospital admissions
- Implementing behavior interventions and decision support to guide providers in diagnosing and treating infections have proven effective
- Polymerase chain reaction (PCR) testing allows for quick and expansive pathogen identification and earlier targeted treatment
- In 2014, Saint Luke's Health System implemented use of a gastrointestinal (GI) PCR panel
- We have taken a multi-disciplinary approach to optimizing GI PCR panel including adding templated comments with positive results, hosting a Diagnostic Stewardship Summit, and developing clinical decision support to guide appropriate test use
- Our Antimicrobial and Diagnostic Advisement Program (ADAP) has taken an active role in collaborating and leading ID diagnostic optimization
- Saint Luke's Health System includes academic, community, and critical access hospitals in the Kansas City region

Objective

• To characterize the evolution of improving diagnostic stewardship applications with a GI PCR panel test since implementation in 2014

GI PCR Quality Improvement Results

- Evaluated the pre-post effect of EMR-embedded GI PCR treatment recommendations on appropriate antimicrobial use within 24 hours of results
- Comparison groups:
- Pre-implementation (Oct 2018-March 2019, n=258)
- Post-implementation (Jan 2020-Feb 2020, n=119)
- Post-implementation group had higher rate of appropriate antimicrobial prescribing (77.9 vs 89.1%, p=0.01)

Matthew Humphrey, Laura Aragon, PharmD, BCIDP, Cindy Essmyer, MD



KANSAS CITY, MISSOURI

ponent	Ref Range & Units		
pylobacter	Not Detected, Not Applicable	Not Detected	Negative ^R
ridium difficile toxin A/B	Not Detected, Not Applicable	Not Detected	
mment Detection of Clostridium dif	ficile may reflect asymptomatic carriag	e or Clostridium difficile-ass	ociated diarrhea.
omonas shigelloides	Not Detected	Not Detected	Negative ^R
onella	Not Detected	Not Detected	Negative ^R
0	Not Detected	Not Detected	Negative ^R
o cholerae	Not Detected	Not Detected	Negative ^R
nia enterocolitica	Not Detected	Not Detected	
oaggregative E. coli (EAEC)	Not Detected	Not Detected	Negative ^R
opathogenic E. coli (EPEC)	Not Detected	Not Detected	Negative ^R
rotoxigenic E. coli (ETEC)	Not Detected	Not Detected	Negative ^R
a-like toxin-producing E. coli (STEC)	Not Detected	Not Detected	
li 0157	Not Detected	Not Detected	
ella/Enteroinvasive E. coli (EIEC)	Not Detected	Not Detected	Negative ^R
tosporidium	Not Detected	Not Detected	Negative ^R
ospora cayetanensis	Not Detected	Not Detected	Negative ^R
noeba histolytica	Not Detected	Not Detected	Negative ^R
lia lamblia	Not Detected	Not Detected	Negative ^R
ovirus F 40/41	Not Detected, Not Applicable	Not Detected	Negative ^R
ovirus	Not Detected, Not Applicable	Not Detected	Negative ^R
virus GI/GII	Not Detected	Not Detected	Negative ^R
virus A	Not Detected	Detected !	
omment Supportive care recommended.			
virus	Not Detected	Not Detected	Negative ^{R, CM}
anal Stool Consistency		Liquid	

B SLC Gastrointestinal P Gastrointestinal Pathogen Panel ⁷ Diagnostics Please answer the question Note: If C. Difficle PCR is GI PCR Decision Supp O Chronic diarrhea? (> / = 🔵 Acute diarrhea? (< 2 mc Override Order: C. diff P Lab criteria for appropri Override Order: C. diff PC Additional Orders Diagnostics Please answer the Note: If C. Diffi Chronic diari Acute diarrh 🔘 Need for Please answ Note: If C. Dif GI PCR De Acute diarr Recent a Clost 🔿 Recent antibiotic usage - N

ordering

🖌 Orders

- making

The authors have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter

tic		λ
,		
	<u> </u>	Ļ

Clinical Decision Support

Smart order set providing interactive guidance via decision support to optimize

	Clear All Orders
athogen Panel 😞 🗙	R <u>e</u> move Order Sets
orders with decision support.	
ns in GI PCR Decision Support appropriately to guide you through the evidence based decision tree for the Gastrointestinal Pathogen pan positive within the past 7 days OR if GI PCR has been resulted within the past 7 days, the questions/order will be suppressed.	el.
ort	
2 months of persistent symptoms)	
nths of persistent symptoms)	
CR and GI PCR	
te testing applies	
R and GI PCR	Click for more
e questions in GI PCR Decision Support appropriately to guide you through the evidence based decision tree for the Gastrointestinal Pathogen panel. Ie PCR is positive within the past 7 days OR if GI PCR has been resulted within the past 7 days, the questions/order will be suppressed.	
Support	
ea? (> / = 2 months of persistent symptoms)	
a? (< 2 months of persistent symptoms)	
biotic usage - YES	
biotic usage - NO	
oderate symptoms, < / days duration	
r hospitalization, fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain, or immunocompromised, < / days duration	
thogen by PCR without C. diff - Routine, Starting today at 1452, Until Thu 8/18, For 48 hours Stool	
ridium Difficile Toxin by PCR	
r more days of symptom duration	
the questions in GI PCR Decision Support appropriately to guide you through the evidence based decision tree for the Gastrointestinal Pathogen panel. ficle PCR is positive within the past 7 days OR if GI PCR has been resulted within the past 7 days, the questions/order will be suppressed.	
cision Support	
rrhea? (> / = 2 months of persistent symptoms)	
hea? (< 2 months of persistent symptoms)	
Intibiotic usage - YES	

Conclusion

- Multi-disciplinary diagnostic stewardship strategies are required to support optimized use of GI PCR panel testing. Antimicrobial Stewardship Programs can lead these initiatives.
- Development of clinical decision support, both during ordering and interpretation, enhances test application
- Collaborative efforts have led to sustained reductions in GI PCR panel use, cost-effective testing, and optimization of post-result clinical decision

Disclosures